Patent · US Active

Antibodies against human IL17 and uses thereof

US8003099B2 · kind B2 · utility

21Cited by

2References

17Claims

0Family size

Assignee

Roche Palo Alto LLC · US

Inventors

Johannes Auer · Schwaigen, DE
Nikolaos Dimoudis · Wielenbach, DE
Guy Georges · Habach, DE
Petra Hanke · Munich, DE
Hendrik Knoetgen · Penzberg, DE
Ekkehard Moessner · Kreuzlingen, CH
Claire Langrish · Redwood City, US

Key dates

Filing date	Sep 29, 2009
Grant date	Aug 23, 2011
Priority date	—
Expiry date	Sep 29, 2029

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10S530/809
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between CH1 and CH2 and/or in the second inter-domain region at amino acid position 327-331 between CH2 and CH3 has advantageous properties for the treatment of inflammatory diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.